Biopharmaceutical company Oculis Holding AG (Nasdaq: OCS) is now the subject of securities fraud investigations by several shareholder rights law firms. This follows the company's disclosure on May 29, 2026, that two Phase 3 clinical trials for its core drug candidate, OCS-01, had failed, causing its stock price to plunge by over 23% in a single day. Firms including Levi & Korsinsky, Pomerantz LLP, and The Schall Law Firm have initiated inquiries.

Catalyst for Legal Scrutiny

The investigations were triggered by the top-line results from the DIAMOND-1 and DIAMOND-2 Phase 3 trials, which Oculis announced on May 29. These global trials, conducted across 119 sites and involving over 800 patients with diabetic macular edema (DME), were designed to evaluate the efficacy and safety of OCS-01 eye drops.

The results showed the trials failed to meet the primary endpoint of improvement in best-corrected visual acuity (BCVA) at week 52. A key secondary endpoint, the proportion of patients achieving a BCVA gain of 15 letters or more, was also not met. Although OCS-01 demonstrated a significant and sustained reduction in retinal thickness in both studies, this anatomical improvement did not translate into functional vision gains. The company concurrently announced it would not submit a New Drug Application to the U.S. FDA for the DME indication and would reallocate resources to other late-stage pipeline projects.

Market Impact and Stock Performance

In reaction to this news, Oculis shares plummeted by $6.95, or 23.44%, on May 29, closing at $22.70. By early June, the stock had declined by more than 60% since the trial results were made public.

Focus of the Investigations

Levi & Korsinsky is currently investigating whether Oculis made false or misleading statements concerning the trial's progress and associated risks. The investigation notes that in an October 2025 fundraising document, the company stated its DME program was on track, with top-line results expected in the second quarter of 2026 and an FDA submission to follow upon positive outcomes.

Financial Position and Future Direction

Despite this setback, Oculis maintains a robust financial position. As of March 31, 2026, the company held approximately $278 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into the second half of 2029. The company is now focusing its efforts on two other late-stage projects: privosegtor for optic neuropathy and licaminlimab for dry eye disease.